Rockwell Collins to Sell Kaiser Optical Systems to Endress+Hauser - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rockwell Collins to Sell Kaiser Optical Systems to Endress+Hauser



Rockwell Collins announced that it has agreed to sell its subsidiary, Kaiser Optical Systems, a spectrographic instrumentation and applied holographic technology company, to Endress+Hauser, a producer of measurement instrumentation and services for industrial process engineering. Terms of the agreement were not disclosed. The sale is expected to be complete in early fiscal 2014 and is subject to customary closing conditions.

Kaiser Optical Systems, located in Ann Arbor, Michigan, became a Rockwell Collins company in 2000 as part of the company’s purchase of K Systems, the parent company of Kaiser Aerospace and Electronics. Principal products include Raman sensors and instrumentation, advanced holographic components for
spectroscopy, telecommunications, astronomy and ultra-fast sciences, and components for aircraft display systems.

Source: Rockwell Collins

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here